Abstract:Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. It is estimated that 13,410 cases will be diagnosed and 8,990 will die of AML in the United States in 2007 (http://seer.cancer.gov). AML is a genetically diverse hematopoietic malignancy with variable response to treatment. Expression profiling of protein-coding genes using DNA microarray in AML has resulted in inconsistent data from different laboratories. Therefore, further validation of these observations in large cohorts and in independent studies is definitely required before clinical application becomes feasible. Recently, Golub and colleagues described a new, bead-based flow cytometric microRNA (miRNAs, miRs) expression profiling method that could successfully classify tumors. MiRNAs are endogenous ∼22 nucleotide non-coding RNAs, which can function as oncogenes and tumor suppressors. To provide new insights into the complex genetic alterations in leukemogenesis and to identify novel markers for diagnosis and treatment of AML, we performed a genome-wide analysis of miRNA expression profiles using the bead-based method on 54 AML samples with common translocations including t(15;17), t(8;21), inv(16), and 11q23 rearrangement, along with normal controls. In both unsupervised and supervised hierarchical cluster analyses, we observed that t(15;17) samples grouped together as one cluster, as do the 11q23 rearrangement samples. Interestingly, t(8;21) and inv(16), both CBF (core-binding factor) AMLs, grouped together as a unique cluster. Forty-one miRNAs exhibited significantly differential expression between different subtypes of AMLs, and/or between AMLs and normal controls. Notably, expression signature of a minimal number of two, three, and seven miRNAs could be used for class prediction of CBF, t(15;17), and 11q23 rearrangement AMLs, respectively, with an overall diagnostic accuracy of 94–96%. We further showed that overexpression of the two discriminatory miRNAs in CBF AML is associated with epigenetic regulation, rather than DNA copy number amplification. Moreover, several important target genes of these discriminatory miRNAs have also been validated. We are currently exploring the role of these discriminatory miRNAs and their critical target genes in the development of AML using in vitro and in vivo models. This work will enhance our understanding of the biological role of these miRNAs and their targets in leukemogenesis.

Study on relationship between different bcr/abl fusion transcripts and clinical manifestations in chronic myeloid leukemia]

[Cytogenetic and Molecular Analysis of 1193 Cases with Chronic Myeloid Leukemia].

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

Cytogenetic Analysis of 1863 Chineses Patients with Chronic Myeloid Leukemia

Clinical and Biological Characteristics of Acute Myeloid Leukemia with 20-29% Blasts: a Retrospective Single-Center Study

Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.

[Effect of Co-Expressing M-bcr/abl and M-Bcr/abl Fusion Gene Transcripts on the Clinical Features of Patients with Chronic Myelogenous Leukemia at Diagnosis].

Types of BCR-ABL Fusion Gene in Chronic Myeloid Leukemia and Its Clinical Significance

MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.

Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival

Association between the BCR-ABL gene transcripts and the laboratory hematological profile

Clinical Significance of Detection of bcr/abl Fusion Gene in theDiagnosis and Minimal Residual Disease of Chronic Myeloid Leukemia

[Detection of Common Fusion Transcript Levels in Untreated Leukemia Patients by Real-Time Quantitative RT-PCR Technique].

Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.

Expression of the CDH13 gene and BCR/ABL fusion gene in chronic myeloid leukemia patients and their relationship

Prevalence and Outcomes of Uncommon BCR‐ABL1 Fusion Transcripts in Patients with Chronic Myeloid Leukaemia: Data from a Single Centre

[Clinical and Laboratory Characteristics of 12 Ph/BCR-ABL Positive Acute Myeloid Leukemia Patients].

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene

Cytogenetic analysis of 362 cases of chronic myeloid leukemia]

[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].